Armata Pharmaceuticals, Inc. (ARMP)
USD 1.95
(-2.5%)
USD 1.95
(-2.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -39.91 Million USD | -10.72% |
| 2022 | -36.05 Million USD | -59.19% |
| 2021 | -22.65 Million USD | -10.81% |
| 2020 | -20.43 Million USD | -12.35% |
| 2019 | -19.75 Million USD | -117.58% |
| 2018 | -9.54 Million USD | -34.9% |
| 2017 | -9.98 Million USD | 26.68% |
| 2016 | -13.46 Million USD | 56.73% |
| 2015 | -10.22 Million USD | 61.82% |
| 2014 | -14.11 Million USD | -299.43% |
| 2013 | -61.6 Million USD | 735.73% |
| 2012 | -3.86 Million USD | 0.0% |
| 2008 | -11.77 Million USD | 73.76% |
| 2007 | -13.8 Million USD | -2.03% |
| 2006 | -32.85 Million USD | 25.19% |
| 2005 | -17.36 Million USD | -13.1% |
| 2004 | -12.49 Million USD | -1037.49% |
| 2003 | -6.19 Million USD | 92.02% |
| 2002 | -16.8 Million USD | 31.79% |
| 2001 | -19.91 Million USD | -231.6% |
| 2000 | -42.34 Million USD | 347.22% |
| 1999 | -9.5 Million USD | 18.29% |
| 1998 | -7.5 Million USD | 43.06% |
| 1997 | -13.3 Million USD | -536.36% |
| 1996 | -10.2 Million USD | 133.67% |
| 1995 | -9 Million USD | -40.0% |
| 1994 | -7 Million USD | -29.63% |
| 1993 | -5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.91 Million USD | -26.4% |
| 2024 Q2 | -11.59 Million USD | 152.52% |
| 2023 FY | - USD | -10.72% |
| 2023 Q1 | -7.95 Million USD | 22.99% |
| 2023 Q2 | -15.66 Million USD | -96.94% |
| 2023 Q4 | -9.28 Million USD | 64.15% |
| 2023 Q3 | -25.9 Million USD | -65.34% |
| 2022 Q2 | -9.02 Million USD | -5.52% |
| 2022 FY | - USD | -59.19% |
| 2022 Q1 | -8.54 Million USD | -48.15% |
| 2022 Q4 | -10.32 Million USD | -23.14% |
| 2022 Q3 | -8.38 Million USD | 7.01% |
| 2021 Q3 | -5.82 Million USD | 1.15% |
| 2021 Q4 | -5.77 Million USD | 1.01% |
| 2021 Q1 | -5.15 Million USD | 16.51% |
| 2021 Q2 | -5.89 Million USD | -14.42% |
| 2021 FY | - USD | -10.81% |
| 2020 Q2 | -4.28 Million USD | 7.27% |
| 2020 Q3 | -5.35 Million USD | -24.86% |
| 2020 Q4 | -6.17 Million USD | -15.3% |
| 2020 FY | - USD | -12.35% |
| 2020 Q1 | -4.62 Million USD | -51.61% |
| 2019 Q1 | -3.48 Million USD | -265.51% |
| 2019 FY | - USD | -117.58% |
| 2019 Q2 | -4.55 Million USD | -30.51% |
| 2019 Q3 | -6.39 Million USD | -40.61% |
| 2019 Q4 | -3.05 Million USD | 52.34% |
| 2018 Q2 | -2.95 Million USD | -2.74% |
| 2018 FY | - USD | -34.9% |
| 2018 Q4 | -954 Thousand USD | 39.24% |
| 2018 Q3 | -1.57 Million USD | 46.92% |
| 2018 Q1 | -2.87 Million USD | -26.16% |
| 2017 Q2 | 83 Thousand USD | 102.46% |
| 2017 Q4 | -2.28 Million USD | -268.06% |
| 2017 Q1 | -3.37 Million USD | -162.13% |
| 2017 FY | - USD | 26.68% |
| 2017 Q3 | -620 Thousand USD | -846.99% |
| 2016 Q1 | -5.84 Million USD | -67.61% |
| 2016 FY | - USD | 56.73% |
| 2016 Q3 | -4.34 Million USD | -34.28% |
| 2016 Q4 | 5.43 Million USD | 225.21% |
| 2016 Q2 | -3.23 Million USD | 44.63% |
| 2015 Q3 | -10.18 Million USD | 35.88% |
| 2015 Q2 | -15.88 Million USD | -258.47% |
| 2015 Q1 | 10.02 Million USD | 268.12% |
| 2015 FY | - USD | 61.82% |
| 2015 Q4 | -3.48 Million USD | 65.78% |
| 2014 Q2 | -22.75 Million USD | -555.99% |
| 2014 Q3 | -29.28 Million USD | -28.68% |
| 2014 Q4 | -5.96 Million USD | 79.63% |
| 2014 FY | - USD | -299.43% |
| 2014 Q1 | 4.99 Million USD | 125.41% |
| 2013 Q3 | 44.09 Million USD | 1844.91% |
| 2013 Q4 | -19.63 Million USD | -144.54% |
| 2013 Q2 | 2.26 Million USD | 388.79% |
| 2013 Q1 | -785 Thousand USD | 0.0% |
| 2013 FY | - USD | 735.73% |
| 2012 FY | - USD | 0.0% |
| 2009 Q1 | -1.02 Million USD | -116.73% |
| 2009 Q2 | -6.34 Million USD | -520.65% |
| 2009 Q3 | 1.49 Million USD | 123.49% |
| 2008 Q3 | -2.64 Million USD | 22.81% |
| 2008 FY | - USD | 73.76% |
| 2008 Q4 | 6.11 Million USD | 331.18% |
| 2008 Q1 | -3.1 Million USD | -50.73% |
| 2008 Q2 | -3.42 Million USD | -10.38% |
| 2007 Q1 | -33.19 Million USD | -740.78% |
| 2007 Q2 | -3.34 Million USD | 89.93% |
| 2007 Q3 | -3.06 Million USD | 8.38% |
| 2007 Q4 | -2.05 Million USD | 32.79% |
| 2007 FY | - USD | -2.03% |
| 2006 Q1 | -1.66 Million USD | 49.71% |
| 2006 Q2 | -3.44 Million USD | -106.59% |
| 2006 Q4 | -3.94 Million USD | -67.36% |
| 2006 Q3 | -2.35 Million USD | 31.58% |
| 2006 FY | - USD | 25.19% |
| 2005 Q2 | -4.53 Million USD | -13.82% |
| 2005 FY | - USD | -13.1% |
| 2005 Q3 | -3.44 Million USD | 24.08% |
| 2005 Q1 | -3.98 Million USD | -113.23% |
| 2005 Q4 | -3.31 Million USD | 3.52% |
| 2004 Q3 | -3.77 Million USD | -4.95% |
| 2004 Q4 | -1.86 Million USD | 50.54% |
| 2004 Q1 | -4.26 Million USD | -60.44% |
| 2004 Q2 | -3.59 Million USD | 15.62% |
| 2004 FY | - USD | -1037.49% |
| 2003 Q2 | -2.94 Million USD | -112.71% |
| 2003 Q4 | -4.25 Million USD | -430.47% |
| 2003 FY | - USD | 92.02% |
| 2003 Q1 | 534 Thousand USD | 329.13% |
| 2003 Q3 | 468 Thousand USD | 928.87% |
| 2002 FY | - USD | 31.79% |
| 2002 Q1 | -5.26 Million USD | 53.72% |
| 2002 Q2 | -5.37 Million USD | -3.07% |
| 2002 Q3 | -3.57 Million USD | 33.28% |
| 2002 Q4 | -2.58 Million USD | 90.94% |
| 2001 Q3 | 13.4 Million USD | 1009.48% |
| 2001 Q4 | -11.55 Million USD | -182.91% |
| 2001 Q2 | -2.55 Million USD | 67.56% |
| 2001 Q1 | -3.92 Million USD | 35.83% |
| 2001 FY | - USD | -231.6% |
| 2000 Q3 | 1.15 Million USD | 935.21% |
| 2000 FY | - USD | 347.22% |
| 2000 Q4 | -7.19 Million USD | -125.18% |
| 2000 Q2 | -3.49 Million USD | -52.36% |
| 2000 Q1 | -2.29 Million USD | 69.78% |
| 1999 FY | - USD | 18.29% |
| 1999 Q1 | -2.4 Million USD | -221.05% |
| 1999 Q2 | -2.5 Million USD | 134.78% |
| 1999 Q3 | -2.8 Million USD | 1037.5% |
| 1999 Q4 | 1.3 Million USD | -183.52% |
| 1998 Q2 | -2.6 Million USD | 21.21% |
| 1998 Q4 | 2 Million USD | 159.38% |
| 1998 Q3 | -3.2 Million USD | -23.08% |
| 1998 Q1 | -3.3 Million USD | 23.26% |
| 1998 FY | - USD | 43.06% |
| 1997 Q3 | -3.3 Million USD | 8.33% |
| 1997 Q1 | -3.5 Million USD | -84.21% |
| 1997 FY | - USD | -536.36% |
| 1997 Q4 | -4.3 Million USD | -30.3% |
| 1997 Q2 | -3.6 Million USD | -2.86% |
| 1996 FY | - USD | 133.67% |
| 1996 Q4 | -1.9 Million USD | 51.28% |
| 1996 Q3 | -3.9 Million USD | -137.14% |
| 1996 Q1 | -2.8 Million USD | 12.5% |
| 1996 Q2 | 10.5 Million USD | 475.0% |
| 1995 Q3 | -2.3 Million USD | 8.0% |
| 1995 Q4 | -3.2 Million USD | -39.13% |
| 1995 FY | - USD | -40.0% |
| 1995 Q1 | -2.6 Million USD | -18.18% |
| 1995 Q2 | -2.5 Million USD | 3.85% |
| 1994 Q4 | -2.2 Million USD | 0.0% |
| 1994 FY | - USD | -29.63% |
| 1994 Q1 | 100 Thousand USD | 101.82% |
| 1994 Q2 | -2.1 Million USD | -2200.0% |
| 1994 Q3 | -2.2 Million USD | -4.76% |
| 1993 Q4 | -5.5 Million USD | -5600.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | -26.012% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 21.928% |
| Azitra, Inc. | -10.67 Million USD | -274.002% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -387.995% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -481.701% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | -39.573% |
| CEL-SCI Corporation | -27.56 Million USD | -44.837% |
| iBio, Inc. | -14.02 Million USD | -184.702% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -61.396% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -97.786% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | -74.887% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -187.695% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -731.625% |
| NanoViricides, Inc. | -7.75 Million USD | -414.6% |
| Oragenics, Inc. | -20.87 Million USD | -91.201% |
| BiomX Inc. | -22.81 Million USD | -74.964% |
| BiomX Inc. | -22.81 Million USD | -74.964% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 442.614% |
| Palatin Technologies, Inc. | -29.03 Million USD | -37.501% |
| Scorpius Holdings, Inc. | -35.08 Million USD | -13.783% |